169 related articles for article (PubMed ID: 17929270)
1. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Dubovsky JA; McNeel DG
Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR; Torensma R; de Vries TJ; Schreurs MW; de Bruijn DR; Kater-Baats E; Ruiter DJ; Adema GJ; van Muijen GN; van Kessel AG
Cancer Res; 2000 Mar; 60(6):1654-62. PubMed ID: 10749136
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
5. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
6. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
7. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
8. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
9. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
[TBL] [Abstract][Full Text] [Related]
10. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
12. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
Ayyoub M; Taub RN; Keohan ML; Hesdorffer M; Metthez G; Memeo L; Mansukhani M; Hibshoosh H; Hesdorffer CS; Valmori D
Cancer Immun; 2004 Aug; 4():7. PubMed ID: 15298487
[TBL] [Abstract][Full Text] [Related]
13. SSX expression in gynecological cancers and antibody response in patients.
Hasegawa K; Koizumi F; Noguchi Y; Hongo A; Mizutani Y; Kodama J; Hiramatsu Y; Nakayama E
Cancer Immun; 2004 Dec; 4():16. PubMed ID: 15603546
[TBL] [Abstract][Full Text] [Related]
14. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas.
Mashino K; Sadanaga N; Tanaka F; Yamaguchi H; Nagashima H; Inoue H; Sugimachi K; Mori M
Br J Cancer; 2001 Sep; 85(5):713-20. PubMed ID: 11531257
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression of cancer-testis antigens in human prostate cancer.
Heninger E; Krueger TE; Thiede SM; Sperger JM; Byers BL; Kircher MR; Kosoff D; Yang B; Jarrard DF; McNeel DG; Lang JM
Oncotarget; 2016 Dec; 7(51):84359-84374. PubMed ID: 27769045
[TBL] [Abstract][Full Text] [Related]
16. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
17. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
[TBL] [Abstract][Full Text] [Related]
18. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.
Wu LQ; Lu Y; Wang XF; Lv ZH; Zhang B; Yang JY
Life Sci; 2006 Jul; 79(8):744-8. PubMed ID: 16546222
[TBL] [Abstract][Full Text] [Related]
20. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
